How Radiomics can support your clinical trials
Beyond typical services of an imaging CRO, Radiomics is an expert partner for the pharmaceutical industry. Using our proprietary radiomics analysis, combined with our clinical and therapeutic expertise, we provide insight-based decision-making solutions to optimize the clinical drug development trajectory. Our expertise focus on:
DISEASE DETECTION & CHARACTERIZATION
Traditional endpoints are known to be rather insensitive to disease progression (such as RECIST or FEV1) or to require a very long follow-up period for patients in clinical trials (exacerbation, survival, etc). Our proprietary advanced image analysis technologies, characterize disease shape, size, texture and intensity in 3D/4D space with the aim to unravel hidden data embedded within standard medical images. By identifying imaging characteristics that change as disease progresses, additional quantifiable and very sensitive endpoints related to the safety and efficacy of the treatment can be defined.
TREATMENT EVALUATION
Our radiomics image analysis provides an array of endpoints for the evaluation and early detection of safety and efficacy of drugs, which are sensitive to the most subtle treatment-induced changes. The use of this technology in Phase I and II development facilitates shorter trials which require fewer patients, but also provide insights for the decision-making process and in the optimization of the subsequent phases.
PATIENT SELECTION & STRATIFICATION
Our treatment evaluation approach identifies early on in the development trajectory large variabilities in treatment response. If present, Radiomics can help to stratify the exact responders’ phenotype. Radiomics-based imaging biomarkers can also be used to accurately detect several relevant biological pathways.
PREDICTION OF TREATMENT EFFECT
We have developed and prospectively validated treatment-specific image-based prediction signatures for individual patient use....
More Info Less Info